Background {#Sec1}
==========

Autosomal dominant polycystic kidney disease (ADPKD) is a dominantly inherited systemic disease characterised by progressive growth of renal cysts. Recent studies in Europe estimate the prevalence at around one in 3000 people \[[@CR1], [@CR2]\], equivalent to fewer than 200,000 cases in the European Union. While a rare disease overall, ADPKD is one of the most common hereditary diseases.

Clinical symptoms of renal disease can occur at any age but typically begin in the third or fourth decade of life \[[@CR3]\]. Kidney volume growth is due to cyst expansion and precedes functional renal deterioration (as measured by glomerular filtration rate \[GFR\]) by several decades. Compensatory hyperfiltration in surviving nephrons initially maintains renal function near normal values. Around 50% of patients require renal replacement therapy due to kidney failure, which typically develops in the fourth to sixth decade of life \[[@CR3]\]. Conventional treatments are tailored to reduce morbidity due to complications of the disease \[[@CR4]\]. However, new treatment options slowing down the progression of the disease have now become available \[[@CR5]\]. Transplantation is the treatment of choice for end-stage renal disease (ESRD) in ADPKD \[[@CR4]\]. Still only a limited number of patients with ESRD undergo transplantation instead of dialysis as initial renal replacement therapy \[[@CR6]\].

There is sparse information on the economic burden of ADPKD. One study showed an association between direct medical costs and advanced renal dysfunction in patients with polycystic kidney disease who were free of indications of dialysis or transplantation at baseline \[[@CR7]\]. A recent study of early-stage ADPKD patients with normal kidney function, found that these patients added a sizable economic burden to the health care system relative to the general population \[[@CR8]\]. In a cross-sectional analysis, ADPKD patients, compared to chronic kidney disease (CKD) patients, were found to be younger and generally healthier \[[@CR9]\]. However, kidney-related complications and major kidney procedures were more common among ADPKD patients. Further, a retrospective study of medical resource utilisation in ESRD showed that ADPKD patients were younger at dialysis initiation and had lower medical costs compared to control patients with ESRD etiologies other than ADPKD \[[@CR10]\].

Cost estimates of ADPKD have been predominantly based on US reimbursement claims data and focused on direct medical resource utilisation for a subset of the population. The objective of this study was to estimate the annual direct and indirect costs of patients with ADPKD, by severity of the disease, in the Nordics.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This was a cross-sectional study of patients with ADPKD based on data collected from medical charts and patient self-administered questionnaires. Nine nephrology clinics participated; four in Denmark, one in Finland, two in Norway and two in Sweden. Between April and December 2014, we screened and enrolled convenience samples of subjects from each clinic. Patients were recruited by phone or in-person during routine clinical care.

Ethics approvals for the study were granted by the Helsinki University Hospital Ethical Review Board, the Regional Committee of Medical and Health Research Ethics in Oslo (REC South East) and the Regional Ethical Review Board in Stockholm. While the study was reported to the Danish Health and Medicines Authority, formal ethics approval was not required due to the non-interventional design. The study protocol and consent procedures were also reviewed and approved by the participating clinics.

Sample and inclusion criteria {#Sec4}
-----------------------------

Subjects were enrolled into four mutually exclusive strata using a hierarchical approach:maintenance dialysis: patients currently on dialysis with or without transplanted kidneytransplant recipients: patients with a functioning transplanted kidney, currently not on dialysisCKD stages 4--5: patients not currently on dialysis/no previous transplantCKD stages 1--3: patients not currently on dialysis/no previous transplant

Disease severity among ADPKD patients was determined using the estimated GFR (eGFR), as calculated by each respective laboratory; eGFR \<30 ml/min/1.73m^2^ for CKD stages 4--5 and eGFR ≥30 ml/min/1.73m^2^ for CKD stages 1--3. The most recent laboratory value was used to establish disease severity at enrolment date. Enrolment of patients was tracked in order to achieve a balanced recruitment across the four groups.

Subjects were eligible for enrolment in the study if they were 18 years of age or older and had been managed for ADPKD at the clinic during the past 12 months. Furthermore, participants were required to have had an eGFR value recorded in the past 12 months (not applicable if on dialysis). Subjects were excluded if they had been involved in a clinical trial in the past 12 months that resulted in a change in the standard of care received. Patients on maintenance dialysis were required to have had initiated dialysis at least six months prior to enrolment. Similarly, patients with a working kidney transplant were required to have had undergone the transplant procedure at least six months prior to enrolment. Finally, informed written consent was required for participation in the study.

Data collection {#Sec5}
---------------

Data were extracted from medical charts using a standardised case report form (CRF) and complemented with a self-administered questionnaire \[see Additional files [1](#MOESM1){ref-type="media"} and [2](#MOESM2){ref-type="media"}\]. The CRF and questionnaire were matched for each subject using anonymised subject identifiers.

The standardised CRF allowed for uniform collection of demographic data, disease history and annual ADPKD-related resource utilisation. The CRF covered the 12-month period prior to patient enrolment (enrolment date).

The questionnaire, completed by patients, included complementary questions on ADPKD-related healthcare services received in the past four weeks outside of the primary nephrology clinic, including informal care. Indirect morbidity measures in terms of time missed from work and impairment of work productivity were obtained using the Work Productivity and Activity Impairment (WPAI:GH) questionnaire \[[@CR11]\].

Cost estimation {#Sec6}
---------------

A societal perspective was used to estimate total costs. We summarised both direct and indirect annual costs related to ADPKD. Resources used in the past 12 months were quantified for each patient and multiplied by unit costs to derive total annual costs. Unit costs for healthcare services (e.g. primary care visit or blood transfusion) were obtained from local and national pricelists as presented in Table [1](#Tab1){ref-type="table"}. Additional costs were derived from public reports and national statistics offices (e.g. daily cost of peritoneal dialysis or gross earnings/employment rates).Table 1Data sources for estimating costsType of dataCountrySourceDirect costs^a^DenmarkDanish Medicines Agency \[[@CR13]\]\
Statens Serum Institut \[[@CR14]\]\
The Capital Region of Denmark \[[@CR15]\]\
Rigshospitalet \[[@CR16]\]FinlandPharmaceuticals Pricing Board \[[@CR17]\]\
The Social Insurance Institution of Finland \[[@CR18]\]\
The Hospital District of Helsinki and Uusimaa \[[@CR19], [@CR20]\]\
National institute for health and welfare \[[@CR21]\]\
Kuopio University Hospital \[[@CR22]\]NorwayNorwegian Medicines Agency \[[@CR23]\]\
Norwegian Directorate of Health \[[@CR24], [@CR25]\]\
Ministry of Health and Care Services \[[@CR26]\]SwedenDental and Pharmaceutical Benefits Agency \[[@CR27]\]\
Swedish Association of the Pharmaceutical Industry \[[@CR12]\]\
Region Skåne \[[@CR28]\]\
Stockholm County Council \[[@CR29]\]Indirect costsDenmarkStatistics Denmark \[[@CR30], [@CR31]\]\
Eurostat \[[@CR32]\]\
KPMG \[[@CR33]\]FinlandStatistics Finland \[[@CR34], [@CR35]\]NorwayStatistics Norway \[[@CR36]--[@CR38]\]\
KPMG \[[@CR33]\]SwedenStatistics Sweden \[[@CR39], [@CR40]\]\
Swedish Tax Agency \[[@CR41]\]^a^Transportation costs (to and from haemodialysis) were based on answers in the self-administered questionnaire: taxi, 15 km; public transport, 30 min duration; car, 30 km

Medical resource utilisation was analysed in terms of hospitalisation, outpatient visits, primary care visits, transportation, surgical procedures, diagnostic tests and pharmacotherapy. Pharmacotherapy costs were estimated using conservative dosage estimates as per the drug label \[[@CR12]\] for the following classes: antihypertensives, phosphate binders, erythropoiesis-stimulating agents (ESAs), analgesics for kidney pain, vitamin D analogues and immunosuppressive agents.

Indirect costs included informal care and productivity loss. Cost of informal care was based on hours of help from family and friends in the patient's home and calculated using data on average national gross earnings. Productivity loss was estimated using the human capital approach, taking the patient's perspective and counting every lost hour of work as lost production and income \[[@CR42]\]. Age- and sex-dependent gross earnings and employment rates were obtained from official statistics offices in each country, with employment overheads and benefits added on top. It was assumed that ADPKD patients would have had the same employment rate as the general population had they not been ill.

Annual cost estimates were derived using national cost data and expressed in the local currency of each respective country (2014 values).

Statistical analyses {#Sec7}
--------------------

Summary statistics were calculated, including means and standard deviations (SDs) for continuous variables and frequency distributions for categorical variables. We presented costs as means and used non-parametric bootstrapping procedures to derive 95% confidence intervals. Differences across strata were evaluated using the Kruskal--Wallis and χ^2^/Fisher's exact tests as appropriate. Resource utilisation in the past four weeks, as captured in the self-administered questionnaire, was extrapolated to one year. Data management and analysis were performed using Stata 12.1 (StataCorp LP, College Station, TX, USA).

Results {#Sec8}
=======

Demographic and clinical characteristics {#Sec9}
----------------------------------------

A total of 266 patients were contacted. Of these 243 (91%) provided consent to participate and were enrolled into the four disease strata: CKD stages 1--3 (n = 64), CKD stages 4--5 (n = 55), transplant (n = 61), and dialysis (n = 63). Overall, 241 (99%) of participants completed the questionnaire.

Dialysis and transplant patients tended to be older than patients in earlier stages of the disease; those younger than 65 years were 80% in patients with CKD stages 1--3, 76% in CKD stages 4--5, 54% in dialysis patients and 70% in transplant recipients. Mean age for initiation of dialysis was 59 years in the dialysis stratum and the average age at the time of kidney transplantation was 52 years. Among those on dialysis, only two patients (3%) had received both haemodialysis and peritoneal dialysis in the past 12 months. No differences between disease strata were seen in sex and BMI (Table [2](#Tab2){ref-type="table"}). Employment rates were lowest in the dialysis stratum (21%), with corresponding rates of 44% in transplant recipients, 49% in CKD stages 4--5 and 63% in CKD stages 1--3.Table 2Patient characteristics at enrolment datePatient characteristicCKD 1--3 (n = 64)CKD 4--5 (n = 55)Dialysis (n = 61)Transplant (n = 63)*P* valueCountry, n (%)^a^\<0.0001 Denmark26 (41)32 (58)32 (52)28 (44) Sweden19 (30)12 (22)14 (23)13 (21) Norway19 (30)11 (20)4 (7)16 (25) Finland0 (0)0 (0)11 (18)6 (10)Sex (female), n (%)38 (59)29 (53)33 (54)31 (49)0.7144Age (years), mean ± SD^b^52 ± 1357 ± 1264 ± 1059 ± 10\<0.0001BMI (≥30 kg/m^2^), n (%)10 (16)11 (20)15 (25)14 (22)0.7667Currently employed, n (%)40 (63)27 (49)13 (21)28 (44)\<0.0001Currently employed (aged \<65 years), n (%)40 (78)27 (64)12 (38)26 (59)\<0.0001Comorbidities (≥1), n (%)43 (67)44 (80)61 (100)45 (76)\<0.0001Dialysis in the past 12 months, n (%) ^a^..61 (100)5 (8)\<0.0001 Haemodialysis..51 (84)5 (100)1.0000 Peritoneal dialysis..12 (20)0 (0)0.5754*P* values calculated with χ^2^ test unless otherwise specified*SD* standard deviation, *BMI* body mass index^a^Fisher's exact test^b^Kruskal--Wallis test

Medical resource utilisation {#Sec10}
----------------------------

Medical resource utilisation differed substantially between disease strata (Table [3](#Tab3){ref-type="table"}). In general, dialysis patients had the highest number of hospitalisations and outpatient visits, followed by transplant recipients and other dialysis-independent patients. This difference, however, was not observed for primary care visits, as reported in the self-administered questionnaire.Table 3Annual resource utilisationMean resource utilisation, past 12 months ± SDCKD 1--3 (n = 64)CKD 4--5 (n = 55)Dialysis (n = 61)Transplant (n = 63)*P* valueNumber of hospitalisations0.2 ± 0.60.5 ± 1.11.8 ± 2.30.6 ± 1.0\<0.0001Number of hospital days0.9 ± 3.12.3 ± 6.99.2 ± 13.64.4 ± 10.2\<0.0001Number of hospital days (at least one hospitalisation)6.9 ± 6.58.7 ± 11.615.7 ± 14.712.4 ± 14.10.1878Number of outpatient visits^a^5.2 ± 10.58.2 ± 17.115.2 ± 24.111.6 ± 13.7\<0.0001Number of primary care visits^b^2.2 ± 5.53.8 ± 16.81.9 ± 8.01.2 ± 3.80.6401Number of surgical procedures0.1 ± 0.40.3 ± 0.71.6 ± 3.10.6 ± 1.3\<0.0001Hours of help: Healthcare professional^b^27.0 ± 149.81.8 ± 9.617.1 ± 61.26.4 ± 40.40.1155Hours of help: Home care assistant^b^0.0 ± 0.00.2 ± 1.827.6 ± 132.60.8 ± 3.8\<0.0001Hours of help: Family member or friend^b^3.1 ± 18.227.0 ± 84.6104.8 ± 325.111.0 ± 31.0\<0.0001*P* values calculated with Kruskal--Wallis test^a^Excluding visits for maintenance dialysis^b^Based on the past 4 weeks, self-reported

Only 8% of CKD stages 1--3 patients had a surgery related to ADPKD in the past year, compared to 18% of CKD stages 4--5 patients, 29% of transplant recipients and 49% of dialysis patients. Consequently, there was a significant difference in the mean number of surgical procedures in the past year between the disease strata, ranging from 0.1 in patients with CKD stages 1--3 to 1.6 in dialysis patients. Among transplant recipients, 10% had received the transplant in the past year. Similarly, 25% of dialysis patients had initiated treatment in the past year.

Dialysis patients were generally prescribed more drugs compared to the other disease states; 95% of dialysis patients used phosphate binders, 80% used erythropoiesis-stimulating agents (ESAs) and 97% were prescribed vitamin D analogues (Table [4](#Tab4){ref-type="table"}). Analgesics for kidney pain were, however, most common in CKD stages 4--5, used by 27% compared to 16--23% in the other disease strata. Almost all patients with CKD stages 4--5 (98%) were prescribed antihypertensives.Table 4Annual drug utilisationProportion (%) of patients using drug class, past 12 monthsCKD 1--3 (n = 64)CKD 4--5 (n = 55)Dialysis (n = 61)Transplant (n = 63)*P* valueAntihypertensives849884870.0275Phosphate binders0219514\<0.0001ESAs2138015\<0.0001Analgesics for kidney pain^a^172825170.4149Vitamin D analogs^a^14579743\<0.0001Immunosupressants^a^007100\<0.0001Other drugs19369041\<0.0001*P* values calculated with Fisher's exact test unless otherwise specified*ESA* Erythropoiesis-stimulating agent^a^χ^2^ test

Among dialysis patients 59% travelled by taxi to receive their treatment, while 35% drove and 6% used public transport. Forty-three percent travelled for at least 30 min one-way to receive treatment.

Activity and work impairment {#Sec11}
----------------------------

The levels of general daily activity impairment and productivity impairment due to health problems differed with disease severity. Activity impairment was highest among dialysis patients with 53% but also substantial at 30% in both patients with CKD stages 4--5 and among transplant recipients (Table [5](#Tab5){ref-type="table"}). Among those employed, an average of 4--26% of work time was missed due to health problems, while patients estimated 7--26% of time lost while at work, depending on disease severity. Taken together, overall work impairment due to health was significantly different between disease strata. Work impairment was highest among dialysis patients (42%), followed by CKD stages 4--5 (23%), transplant recipients (16%) and CKD stages 1--3 (9%).Table 5Productivity lossWPAI-GH^a^, percent (%) ± SDCKD 1--3 (n = 61)CKD 4--5 (n = 53)Dialysis (n = 57)Transplant (n = 63)*P* valueActivity impairment due to health16.7 ± 24.429.4 ± 28.052.6 ± 27.230.4 ± 27.5\<0.0001Overall work impairment due to health8.7 ± 14.622.8 ± 28.741.8 ± 33.516.4 ± 23.10.0025Work time missed due to health (absenteeism)4.2 ± 17.38.3 ± 18.925.9 ± 32.84.6 ± 19.60.0014Impairment while working due to health (presenteeism)7.4 ± 12.218.8 ± 24.125.8 ± 23.915.0 ± 20.80.0109*P* values calculated with Kruskal--Wallis test*WPAI-GH* Work Productivity and Activity Impairment-General Health^a^Patients were asked to estimate impairment in the past 7 days (recall period)

Annual costs associated with ADPKD {#Sec12}
----------------------------------

Costs are presented by disease severity and expressed in each respective local currency (Tables [6](#Tab6){ref-type="table"}, [7](#Tab7){ref-type="table"}, [8](#Tab8){ref-type="table"} and [9](#Tab9){ref-type="table"}). Average total annual costs were highest for dialysis patients, followed by transplant recipients, patients in CKD stages 4--5 and CKD stages 1--3 (P \< 0.0001, for all countries). Compared to CKD stages 1--3, annual costs were almost twice as high in CKD stages 4--5, two to three times higher in transplant recipients, and seven to nine times higher in dialysis patients. Differences between disease strata were even more pronounced when looking at direct costs alone (P \< 0.0001, for all countries). Direct costs were almost twice as high in patients with CKD stages 4--5 compared to stages 1--3, but around six times higher among transplant recipients and 21 times higher among dialysis patients. Direct medical costs were substantial among dialysis patients, with routine dialysis care alone accounting over half of total costs. Productivity loss was a driver of costs across all stages of ADPKD, and especially substantial at around two-thirds of total costs in patients with CKD stages 1--3 and 4--5.Table 6Annual costs in Danish krone (Denmark)Costs in DKK, mean (95% CI)CKD 1--3 (n = 64)CKD 4--5 (n = 55)Dialysis (n = 61)Transplant (n = 63)*P* valueDirect costs28,022 (14,728--50,835)47,203 (35,863--63,990)667,362 (623,398--720,640)196,114 (159,055--237,980)\<0.0001Hospitalisations4736 (1611--10,505)12,224 (4810--24,391)50,954 (34,240--71,642)23,881 (12,072--40,151)\<0.0001Outpatient care visits5596 (3810--7867)9483 (6889--14,515)15,802 (11,175--21,341)14,219 (10,992--18,453)\<0.0001Primary care visits1558 (779--2761)2719 (712--7252)1144 (163--2942)791 (317--1741).5094Surgical procedures2183 (125--7519)6938 (2660--13,242)31,596 (18,141--50,394)4228 (1812--7559)\<0.0001Diagnostic tests1591 (1055--2225)1803 (1239--2542)6081 (4851--7544)3464 (2374--5095)\<0.0001Home care/medical assistance9838 (38--28,949)717 (62--1940)12,399 (4417--23,648)2503 (313--7919).0001Routine dialysis care----441,221 (417,652--462,446)14,377 (3783--28,905)\<0.0001Haemodialysis transportation----41,146 (33,117--49,306)214 (0--1068)\<0.0001Drug use2520 (1404--3856)13,318 (9605--17,716)67,020 (57,869--79,028)132,438 (110,082--158,657)\<0.0001 Antihypertensives391 (295--507)476 (394--559)343 (272--420)401 (303--534).0560 Phosphate binders--1351 (656--2160)10,551 (8212--13,158)521 (123--1242)\<0.0001 ESAs60 (0--245)3366 (1286--5953)23,281 (19,497--26,558)3449 (1459--6102)\<0.0001 Analgesics for kidney pain17 (5--39)90 (21--253)182 (26--534)13 (2--37).1069 Vitamin D analogues2004 (937--3379)6955 (5201--8861)13,309 (12,162--14,207)4593 (3129--6257)\<0.0001 Immunosupressants----5699 (312--14,111)122,984 (100,943--149,412)\<0.0001 Other drugs48 (11--110)1081 (157--2500)13,655 (10,825--16,513)477 (194--932)\<0.0001Indirect costs51,523 (32,278--75,631)94,631 (65,117--126,721)100,970 (67,789--132,323)81,688 (55,334--110,676).0726Productivity loss51,224 (31,835--75,332)92,083 (63,079--123,547)91,373 (59,420--122,164)80,647 (54,460--109,503).3032Informal care299 (0--896)2548 (873--5141)9597 (3801--19,465)1041 (415--1891)\<0.0001Total costs79,544 (54,826--109,204)141,834 (105,601--181,449)768,332 (707,301--830,831)277,802 (227,251--333,023)\<0.0001*P* values calculated with Kruskal--Wallis test*DKK* Danish krone, *ESA* erythropoiesis-stimulating agent, *CI* confidence interval (bias corrected) Table 7Annual costs in euro (Finland)Costs in EUR, mean (95% CI)CKD 1--3 (n = 64)CKD 4--5 (n = 55)Dialysis (n = 61)Transplant (n = 63)*P* valueDirect costs3676 (2223--6190)5883 (4588--7701)64,811 (60,460--70,417)20,305 (16,228--25,166)\<0.0001Hospitalisations507 (172--1125)1309 (515--2611)5455 (3666--7670)2557 (1283--4299)\<0.0001Outpatient care visits1159 (843--1569)2057 (1606--2871)3203 (2329--4230)3197 (2502--4155)\<0.0001Primary care visits237 (117--403)414 (84--1097)174 (50--548)121 (48--265).5094Surgical procedures249 (15--794)511 (154--1098)2562 (1211--5119)1009 (435--1956)\<0.0001Diagnostic tests191 (125--263)237(166--321)659 (511--843)354 (251--496)\<0.0001Home care/medical assistance1048 (4--3049)74 (5--204)1093 (384--2044)260 (28--837).0002Routine dialysis care----42,900 (40,609--44,964)1398 (368--2810)\<0.0001Haemodialysis transportation----4090 (3184--5080)13 (0--25)\<0.0001Drug use284 (175--419)1281 (1008--1600)4675 (4040--5512)11,396 (9404--13,944)\<0.0001 Antihypertensives68 (54--86)113 (95--132)73 (60--86)96 (78--117).0020 Phosphate binders--225 (103--362)1266 (1006--1554)65 (15--148)\<0.0001 ESAs4 (0--15)204 (78--361)1413 (1181--1611)209 (89--370)\<0.0001 Analgesics for kidney pain3 (1--7)14 (5--30)12 (4--25)4 (0--12).1329 Vitamin D analogues198 (93--335)689 (516--878)1318 (1207--1407)455 (310--620)\<0.0001 Immunosupressants----440 (26--1076)10,469 (8516--12,955)\<0.0001 Other drugs10 (3--27)36 (17--61)154 (126--183)99 (48--171)\<0.0001Indirect costs4863 (2986--7132)9904 (6738--13,319)7674 (5195--10,042)7585 (5125--10,494).0925Productivity loss4835 (2959--7104)9667 (6586--13,018)6783 (4586--8815)7488 (5058--10,382).2742Informal care28 (0--83)237 (79--475)891 (353--1807)97 (38--176)\<0.0001Total costs8539 (6042--11,631)15,787 (12,006--20,008)72,486 (67,053--79,025)27,890 (22,669--33,722)\<0.0001*P* values calculated with Kruskal--Wallis test*EUR* euro, *ESA* erythropoiesis-stimulating agent, *CI* confidence interval (bias corrected) Table 8Annual costs in Norwegian krone (Norway)Costs in NOK, mean (95% CI)CKD 1--3 (n = 64)CKD 4--5 (n = 55)Dialysis (n = 61)Transplant (n = 63)*P* valueDirect costs38,676 (18,712--69,343)80,145 (51,159--118,538)851,277 (765,334--959,286)185,108 (131,915--251,557)\<0.0001Hospitalisations12,898 (4387--28,610)33,291 (13,098--66,704)138,766 (93,249--195,108)65,036 (32,637--109,347)\<0.0001Outpatient care visits4425 (3355--5859)8085 (6588--10,612)12,050 (8956--15,673)12,840 (10,094--16,706)\<0.0001Primary care visits691 (345--1224)1205 (246--3192)507 (145--1594)351 (140--772).5094Surgical procedures4209 (89--15,018)23,660 (10,359--40,439)106,888 (67,415--153,360)6798 (1790--14,265)\<0.0001Diagnostic tests1652 (1100--2273)1959 (1417--2622)6423 (5132--8002)3359 (2450--4587)\<0.0001Home care/medical assistance12,317 (48--36,245)885 (66--2396)14,151 (5074--27,170)3090 (359--9872).0002Routine dialysis care----495,052 (468,607--518,867)16,131 (4245--32,431)\<0.0001Haemodialysis transportation----32,460 (25,631--39,573)128 (0--256)\<0.0001Drug use2483 (1472--3707)11,060 (8445--14,068)44,980 (39,925--51,304)77,375 (64,093--95,936)\<0.0001 Antihypertensives530 (435--640)715 (621--808)522 (433--617)567 (461--687).02459 Phosphate binders--1158 (565--1850)8072 (6345--9932)418 (102--944)\<0.0001 ESAs36 (0--148)2036 (778--3600)14,079 (11,772--16,055)2086 (827--3610)\<0.0001 Analgesics for kidney pain16 (6--31)103 (33--251)104 (29--256)33 (3--98).1053 Vitamin D analogues1833 (857--3090)6360 (4761--8104)12,170 (11,121--12,991)4200 (2861--5722)\<0.0001 Immunosupressants----2741 (290--6569)69,324 (56,582--87,711)\<0.0001 Other drugs68 (19--164)688 (181--1422)7292 (5804--8788)746 (353--1326)\<0.0001Indirect costs111,441 (70,268--157,539)204,324 (143,043--268,451)215,588 (144,283--280,047)182,164 (125,099--242,812).0604Productivity loss110,892 (70,085--157,480)199,644 (139,793--263,028)197,961 (129,783--259,106)180,251 (123,425--241,038).2452Informal care548 (0--1645)4680 (1603--9442)17,627 (7001--35,752)1913 (761--3473)\<0.0001Total costs150,117 (104,759--202,958)284,469 (206,680--373,107)1,066,865 (950,458--1,204,094)367,272 (278,949--466,269)\<0.0001*P* values calculated with Kruskal--Wallis test*NOK* Norwegian krone, *ESA* erythropoiesis-stimulating agent, *CI* confidence interval (bias corrected) Table 9Annual costs in Swedish krona (Sweden)Costs in SEK, mean (95% CI)CKD 1--3 (n = 64)CKD 4--5 (n = 55)Dialysis (n = 61)Transplant (n = 63)*P* valueDirect costs28,820 (16,123--50,689)48,624 (36,718--65,151)712,482 (668,060--766,530)173,199 (135,833--218,165)\<0.0001Hospitalisations3812 (1297--8456)9840 (3871--19,716)41,015 (27,561--57,668)19,223 (9717--32,319)\<0.0001Outpatient care visits5878 (4291--7943)10,457 (8193--14,512)16,221 (11871--21,402)16,288 (12,728--21,120)\<0.0001Primary care visits1178 (589--2088)2056 (539--5484)865 (124--2225)598 (120--1077).5094Surgical procedures3349 (187--10,713)7135 (1620--15,769)31,431 (16,065--51,975)8131 (3603--14,557)\<0.0001Diagnostic tests2847 (2244--3509)5810 (4535--7332)25,140 (21,308--29,294)10,987 (8119--14,700)\<0.0001Home care/medical assistance9442 (37--27,461)675 (47--1850)10,525 (3734--20,134)2359 (263--7537).0002Routine dialysis care----488,009 (461940--511,484)15,901 (4185--32,472)\<0.0001Haemodialysis transportation----37,145 (30,444--43,657)269 (0--1344)\<0.0001Drug use2313 (1333--3490)12,651 (9110--16,825)62,131 (54,647--71,169)99,443 (80,719--125,735)\<0.0001 Antihypertensives419 (341--513)666 (556--784)503 (415--603)583 (451--756).0282 Phosphate binders--1244 (598--1996)9788 (7577--12,262)472 (108--1151)\<0.0001 ESAs63 (0--257)3535 (1350--6252)24,450 (20,476--27,892)3622 (1533--6409)\<0.0001 Analgesics for kidney pain14 (5--26)102 (28--255)78 (21--193)15 (2--37).1032 Vitamin D analogues1776 (824--2952)6162 (4613--7852)11,792 (10,796--12,592)4069 (2756--5544)\<0.0001 Immunosupressants----3579 (291--8847)90,205 (72,049--117,127)\<0.0001Other drugs41 (10--95)942 (135--2184)11,941 (9447--14,436)477 (202--909)\<0.0001Indirect costs64,259 (39,484--92,072)128,541 (90,007--169,626)124,957 (85,289--162,184)112,688 (77,160--150,663).0438Productivity loss63,963 (39,446--91,997)126,019 (88,140--165,959)115,458 (77,012--150,462)111,658 (75,795--149,420).1842Informal care296 (0--887)2522 (864--5088)9499 (3762--19,266)1031 (410--1871)\<0.0001Total costs93,079 (64,756--125,857)177,165 (131,147--227,131)837,438 (771,457--903,231)285,887 (228,017--352,229)\<0.0001*P* values calculated with Kruskal--Wallis test*SEK* Swedish krona, *ESA* erythropoiesis-stimulating agent, *CI* confidence interval (bias corrected)

Discussion {#Sec13}
==========

In this study we enrolled 243 ADPKD patients from nine nephrology clinics in Denmark, Finland, Norway and Sweden. For these patients we collected and analysed data from medical charts and self-administered questionnaires. Our findings showed that the economic burden of ADPKD was substantial at all levels of disease and that progression of ADPKD was associated with an increased frequency and intensity of medical resource utilisation.

Mean total direct and indirect costs were approximately twice as high in patients with CKD stages 4--5 compared to CKD stages 1--3. Resource utilisation increased substantially as patients progressed to ESRD, with costs among dialysis patients greatly exceeding that of kidney transplant recipients. The use of immunosuppressants accounted for around half of costs in transplant recipients. Similarly, maintenance dialysis care alone accounted for over half of total costs in dialysis patients, who had the highest number of hospitalisations and outpatient visits. Primary care visits were more frequent in earlier stages of the disease. Lost wages due to reduced productivity were large in absolute terms across all disease strata. General daily activity impairment due to health was highest among dialysis patients who reported an average reduction in activity of over 50%. Activity impairment was also substantial in transplant recipients and in patients with CKD stages 4--5, both at around 30%.

Some limitations of our study should be noted. Selection bias may be an issue as with any observational study. No randomisation was performed and primarily patients who actively sought health care were included. Not all patients in earlier stages of the disease are followed by nephrology clinics and the study design limited the inclusion of transplant recipients to those with a functioning transplant, thus potentially underestimating costs in patients with advanced disease. A proportion of patients with ESRD initiated treatment within 12 months of the enrolment date; however, sensitivity analyses revealed an insignificant impact on mean total costs.

Our study adds to the limited and fragmented literature on cost estimates of ADPKD. To our knowledge this is the first study to provide cost data on an ADPKD population that includes both early stages of the disease, stratified by renal function, and patients with ESRD. A further strength of this study is the enrolment of patients with physician-confirmed diagnosis of ADPKD. Furthermore, in addition to data extraction from medical charts, a self-administered questionnaire, including the WPAI:GH, was used to capture resource utilisation outside of the nephrology clinic and to estimate indirect costs in terms of productivity loss and caregiver support. Finally, we achieved a high response rate with 91% of invited patients agreeing to participate in the study.

Conclusions {#Sec14}
===========

We provide a thorough description of the medical resource utilisation and costs associated with ADPKD across all stages of the disease. Our findings confirm the association between economic burden and progression of ADPKD \[[@CR7]\]. Costs were highest in dialysis patients, driven by maintenance dialysis care, while the use of immunosuppressants was the main cost component for transplant care. Costs were twice as high in patients with CKD stages 4--5 compared to CKD stages 1--3. Consequently, interventions that can slow the progression of the disease have the potential to lead to substantial reductions in costs for the treatment of ADPKD.
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================

 {#Sec15}

Additional file 1:QR ADPKD CRF 20140331 Final v1.1.pdf -- Case report form (CRF) -- Questionnaire used to collect data from patients' medical charts. (PDF 624 kb) Additional file 2:QR ADPKD Additional Questions 20140205 Eng.pdf -- Self-administered questionnaire -- Questionnaire administered to patients. (PDF 16 kb)

ADPKD

:   Autosomal dominant polycystic kidney disease

BMI

:   Body mass index

CKD

:   Chronic kidney disease

CRF

:   Case report form

eGFR

:   Estimated glomerular filtration rate

ESA

:   Erythropoiesis-stimulating agents

ESRD

:   End-stage renal disease

SD

:   Standard deviation

WPAI

:   Work productivity and activity impairment
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